



KERALA MEDICAL SERVICES CORPORATION LTD
 (Dept. of Health & Family Welfare, Govt. of Kerala)
 Thycaud P.O., Thiruvananthapuram-14
 Tele Fax No: 0471-2945647,
 0471-2337353, 0471-2945600
Email id: edrugs.kmscl@kerala.gov.in
 CIN : U24233KL2007SGC021616

Essential Drugs Division
No. KMSCL/ED/18/2025

www.kmscl.kerala.gov.in

Date: 06.05.2026

Corrigendum
Specialty Drugs

Sub: - **KMSCL - E-tender for the Procurement of Specialty Drugs for the year 2026-27 - Final Bid Status —Corrigendum-Published-reg.**

Ref: - 1. E-tender No. KMSCL/ED/SPL/RC/2025/029 Dated 11.12.2025
 2. This office notice of even number dated 13.03.2026 on Final Bid Status

The Price Bids (BOQ) submitted online in response to the e-tender referred 1st above for the Procurement of Specialty Drugs for the year 2026-27 were opened on 29.01.2026 and the Final Bid Status were published on 13.03.2026.

I. NATURAL SURFACTANT (STERILE INTRATRACHEAL SUSPENSION) INJ, Phospholipids concentration ≥25 mg/ml, and also contains at least 100mg of Phospholipids per vial (D03083)

- In case of D03083 – NATURAL SURFACTANT (STERILE INTRATRACHEAL SUSPENSION) INJ,
 - a. The rate quoted by the bidder in the Price bid (BOQ) will not be the sole criteria for selecting the final L1 rate.
 - b. The lowest rate will be arrived by calculating the price quoted by the bidder for 1ml.
- Hence, considering the merits and demerits of the matter, it is decided to reject the offer of M/s. Abbott India Ltd against the tender 1st cited. The revised bid status is mentioned below

SL No	Supplier Name	Rate quoted per ml	Quoted Basic Price per Vial	CGST	SGST	Approved Rate	Status
1	Cipla Ltd	1180	5,900.00	147.5	147.5	6,195.00	L1

II. TAMSULOSIN HYDROCHLORIDE PROLONGED RELEASE AND DUTASTERIDE CAP IP, 0.4 mg + 0.5 mg (D21056)

- Representation was received from M/s. Cipla Ltd, intimating the inability to supply the Tamsulosin Hydrochloride Prolonged Release and Dutasteride Cap IP, 0.4mg + 0.5mg as per the tendered specification and requested, not consider the offer for the item.
- Hence it is decided to reject the offer of M/s. Cipla Ltd for Tamsulosin Hydrochloride Prolonged Release and Dutasteride Cap IP, 0.4mg + 0.5mg against the tender 1st cited. The revised bid status is mentioned below;

SL NO	DRUG CODE	DRUG NAME	STRENGTH	UNIT	SUPPLIER NAME	FINAL RATE	STATUS	SSI/ NON-SSI
1	D21056	TAMSULOSIN HYDROCHLORIDE PROLONGED RELEASE AND DUTASTERIDE CAP IP	0.4 mg + 0.5 mg	1 No	UniCure (India) Ltd	1.3299	L1	NON-SSI
					TAS MED (INDIA) PVT LTD	1.8375	L2	NON-SSI

III. TAMSULOSIN HYDROCHLORIDE PROLONGED RELEASE CAP IP, 0.4mg (D21057)

- Representation was received from M/s. Intas Pharmaceuticals Ltd, intimating the inability to supply the Tamsulosin Hydrochloride Prolonged Release Cap IP, 0.4 mg as per the tendered specification and requested, not consider the offer for the item.
- Hence, it is decided to reject the offer of M/s. Intas Pharmaceuticals Ltd for Tamsulosin Hydrochloride Prolonged Release Cap IP, 0.4 mg against the tender 1st cited. The revised bid status is mentioned below

SL NO	DRUG CODE	DRUG NAME	STRENGTH	UNIT	SUPPLIER NAME	FINAL RATE	STATUS	SSI/ NON-SSI
1	D21057	TAMSULOSIN HYDROCHLORIDE PROLONGED RELEASE CAP IP	0.4 MG	1 NO	Mascot Health Series Pvt. Ltd.	0.7875	L1	NON SSI
2					Medipol Pharmaceutical India (P) Ltd.	0.8295	L2	NON SSI
3					Cotec Health Care Ltd	0.8295	L2	NON SSI
4					UniCure (India) Ltd	0.8698	L3	NON SSI
5					Pure And Cure Healthcare Pvt Limited	0.945	L4	NON SSI
6					TAS MED (INDIA) PVT LTD	1.2075	L5	NON SSI

Corrigendum is hereby made against the notice referred 2nd above on final Bid Status.

Sd/-
MANAGING DIRECTOR
KERALA MEDICAL SERVICES CORPORATION LTD.
(TENDER INVITING AUTHORITY)